Integrin Addressin Interaction
Integrin Addressin Interaction - Related Videos
01:10
Integrins
0 Views •
2023
Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM. Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
01:15
Activation of Integrins
0 Views •
2023
Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling." In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
09:14
Static Adhesion Assay for the Study of Integrin Activation in T Lymphocytes
0 Views •
Cited by 21 •
2014
Static adhesion assay is a powerful tool that can be used to model the interactions between T lymphocytes and other cell types. Interactions are generated by injecting labeled T cells into wells coated with adhesion molecules, while a plate reader is used to quantify the number of adherent cells following serial washes.
05:29
An In Vitro Technique to Study T Cell Interaction with Supported Planar Lipid Bilayers
0 Views •
2025
This video demonstrates an in vitro technique to study immune synapse formation between primary human T cells and supported lipid bilayers (SLB). T cell surface proteins interact with respective ligands immobilized on SLB to form an immune synapse, followed by the movement of lytic granules towards the synapse, which is visualized using fluorescence microscopy.
12:38
Titration ELISA as a Method to Determine the Dissociation Constant of Receptor Ligand Interaction
0 Views •
Cited by 29 •
2018
A detailed protocol to perform a titration ELISA is described. Moreover, a novel algorithm is presented to evaluate titration ELISAs and to obtain a dissociation constant of binding of a soluble ligand to a microtiter plate-immobilized receptor.
FAQs
Chemokine signaling activates leukocyte integrins by increasing their affinity for endothelial binding partners. This change converts a circulating leukocyte from a cell capable of transient vascular contact into one that can attach firmly to the vessel lining. The resulting adhesion is a necessary stage before the cell migrates across the vessel wall toward the affected tissue.
These endothelial addressins provide distinct binding sites for leukocyte integrins and help determine where immune cells can attach within the vasculature. Their tissue-associated distribution gives leukocyte trafficking a degree of anatomical selectivity. Consequently, changing the interaction with one addressin or its integrin partner may influence recruitment to particular vascular tissues rather than suppressing all immune-cell movement equally.
Firm adhesion stabilizes the leukocyte on the endothelial surface after integrin activation, positioning the cell for migration across the vessel wall. This sequence links chemical signaling to physical movement: chemokines regulate integrin affinity, integrin binding secures the cell, and subsequent migration enables immune cells to reach tissue. Disrupting adhesion can therefore reduce downstream inflammatory-cell accumulation.
Pharmacological agents can interfere with the pathway by blocking leukocyte integrins or the endothelial addressins they recognize. Either strategy can weaken the binding needed for firm attachment and reduce subsequent immune-cell recruitment. The distinction is mechanistically important because the drug may act on the circulating leukocyte, the vascular binding site, or the interaction between both cellular components.
Targeting an integrin acts directly on the leukocyte adhesion component, whereas targeting an endothelial addressin interferes with the vascular binding partner. Both approaches can reduce firm attachment, but they represent different pharmacological points of control within the same trafficking process. This distinction helps explain how therapies can modify leukocyte recruitment by acting on either participating cell type.
In multiple sclerosis and inflammatory bowel disease, limiting leukocyte recruitment can provide a therapeutic way to reduce inflammation. Blocking integrins or their endothelial addressins may decrease the number of immune cells that attach to vascular tissue and migrate into affected sites. The interaction therefore connects a cellular adhesion mechanism with disease-oriented strategies for modifying inflammatory responses.
Reducing leukocyte adhesion can lessen immune-cell entry into inflamed tissues, which may produce therapeutic benefit. However, leukocyte trafficking is also part of normal immune surveillance and defense, so broadly altering adhesion can create safety risks. Pharmacological evaluation must therefore consider both the desired reduction in inflammatory recruitment and the consequences of interfering with immune-cell movement.